DeCidE1 Phase 1/2 trial

December 22, 2020December 22, 2020

DPX-Survivac Responses Now Up to 16 Months in Advanced Ovarian Cancer Trial

News

IMV‘s immunotherapy DPX-Survivac plus low-dose chemotherapy continues to show sustained benefits in people with heavily treated advanced ovarian cancer, with some benefits lasting up to 16 months, updated findings from a ... Read more

March 4, 2020March 4, 2020

DPX-Survivac Shows Promise in Advanced OC, Early Phase 2 Data Show

News

Treatment with IMV‘s cancer vaccine DPX-Survivac, combined with intermittent low-dose cyclophosphamide, continues to show promise in women with recurrent, advanced ovarian cancer, updated results from a Phase 1/2 trial show. ... Read more

February 12, 2020February 26, 2020

New Trial Data Continue to Support DPX-Survivac in Treating Advanced Ovarian Cancer

News

Immune responses in women with advanced ovarian cancer being treated with DPX-Survivac in clinical trials continue to support the immunotherapy’s potential, alone or in combination, to be effective in this patient population. DPX-Survivac, ... Read more

April 3, 2019

DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show

News

Treatment with DPX-Survivac plus intermittent low-dose cyclophosphamide continues to show promise in women with advanced recurrent ovarian cancer, the second part of a Phase 1/2 trial shows. Interim data from ... Read more

February 8, 2019

IMV Advances Phase 1b/2 Trial of DPX-Survivac Following Positive Feedback from FDA

News

IMV has completed an amendment to the protocol of its Phase 1/2 clinical trial testing a triple combination of DPX-Survivac, epacadostat, and low-dose chemotherapy in recurrent ovarian cancer. The company now ... Read more

January 16, 2019

Triple Combination Works Well in Recurrent Ovarian Cancer with Smaller Tumors, Study Shows

News

The size of tumors in patients with recurrent ovarian cancer seems to predict responses to a triple combination treatment composed of IMV‘s lead candidate DPX-Survivac, Incyte’s experimental epacadostat, and low-dose chemotherapy, a Phase ... Read more